 |
|
|
| |
The Efficacy and Safety of Maintenance With Doravirine Plus Two NRTIs After Initial Suppression in Adults With HIV-1 in the DRIVE-FORWARD Clinical Trial: Results From the Study Extension Through 192 Weeks
|
| |
| |
IDWeek 2021 Sept 29-Oct 3
Pedro Cahn1; Jean-Michel Molina2; Johan Lombaard3; Kathleen Squires4; Sushma Kumar4; Hong Wan4; Valerie Teal4; Ernest Asante-Appiah4; Peter Sklar4; Elizabeth Martin4; Rima Lahoulou5
1Fundación Huésped, Buenos Aires, Argentina; 2Saint-Louis Hospital and University of Paris, Paris, France; 3Josha Research, Bloemfontein, South Africa; 4Merck & Co., Inc., Kenilworth, NJ, USA; 5MSD France, Puteaux, France
|
| |
|
|
|
|
|
